IRIS
CIANI, ORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.469
NA - Nord America 11.323
AS - Asia 5.367
SA - Sud America 715
Continente sconosciuto - Info sul continente non disponibili 520
AF - Africa 183
OC - Oceania 35
Totale 30.612
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.797
IT - Italia 4.036
RU - Federazione Russa 2.989
FI - Finlandia 1.641
CN - Cina 1.601
SG - Singapore 1.417
IE - Irlanda 1.114
GB - Regno Unito 609
VN - Vietnam 555
BR - Brasile 544
UA - Ucraina 429
DE - Germania 427
HK - Hong Kong 420
CA - Canada 366
FR - Francia 322
BD - Bangladesh 298
SE - Svezia 247
TR - Turchia 227
IN - India 173
NL - Olanda 167
KR - Corea 156
ZA - Sudafrica 94
MX - Messico 81
ID - Indonesia 79
IL - Israele 73
PL - Polonia 69
BG - Bulgaria 58
ES - Italia 56
CZ - Repubblica Ceca 55
KZ - Kazakistan 55
AR - Argentina 46
IQ - Iraq 46
JP - Giappone 44
BE - Belgio 41
PK - Pakistan 38
AU - Australia 30
EC - Ecuador 29
VE - Venezuela 29
AT - Austria 28
IR - Iran 25
RO - Romania 25
CO - Colombia 23
PT - Portogallo 23
AE - Emirati Arabi Uniti 21
MA - Marocco 21
CH - Svizzera 20
LT - Lituania 20
PH - Filippine 18
EU - Europa 17
CL - Cile 16
CR - Costa Rica 16
DK - Danimarca 15
MY - Malesia 15
TN - Tunisia 14
UZ - Uzbekistan 14
EG - Egitto 13
KE - Kenya 13
TT - Trinidad e Tobago 13
AZ - Azerbaigian 12
PE - Perù 12
SA - Arabia Saudita 12
HN - Honduras 11
EE - Estonia 9
HU - Ungheria 9
JM - Giamaica 9
JO - Giordania 9
LV - Lettonia 9
NO - Norvegia 9
GR - Grecia 8
OM - Oman 7
TH - Thailandia 7
KG - Kirghizistan 6
SN - Senegal 6
SV - El Salvador 6
UY - Uruguay 6
BO - Bolivia 5
DZ - Algeria 5
GT - Guatemala 5
LA - Repubblica Popolare Democratica del Laos 5
MD - Moldavia 5
NG - Nigeria 5
PY - Paraguay 5
AL - Albania 4
BY - Bielorussia 4
ET - Etiopia 4
LU - Lussemburgo 4
NP - Nepal 4
SI - Slovenia 4
TW - Taiwan 4
AD - Andorra 3
AM - Armenia 3
BH - Bahrain 3
GE - Georgia 3
LK - Sri Lanka 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PA - Panama 3
PR - Porto Rico 3
SK - Slovacchia (Repubblica Slovacca) 3
AG - Antigua e Barbuda 2
Totale 30.070
Salva come PNG Salva come JPEG
Città #
Ashburn 1.693
Helsinki 1.533
San Jose 1.278
Dublin 1.108
Milan 854
Singapore 685
Chandler 673
Council Bluffs 661
Moscow 611
Hefei 553
Dallas 496
Hong Kong 412
Beijing 351
Jacksonville 336
Rome 306
New York 304
Ann Arbor 258
Los Angeles 233
Southend 215
Toronto 215
The Dalles 175
Edison 166
Columbus 161
Redmond 149
Seoul 149
Dearborn 146
Ho Chi Minh City 144
Lauterbourg 137
Houston 135
Dong Ket 130
Wilmington 116
Boston 108
Hanoi 108
Modena 101
Chicago 98
Lawrence 97
Boardman 93
Naples 90
Buffalo 86
Johannesburg 84
Santa Clara 81
Munich 80
Phoenix 80
Izmir 71
Frankfurt am Main 68
Jakarta 68
São Paulo 66
Tel Aviv 66
Bologna 64
Orem 52
Seattle 52
Almaty 50
Redwood City 50
Turin 49
Atlanta 48
Mountain View 48
Warsaw 48
Palombara Sabina 47
Lappeenranta 46
Montreal 46
Chennai 44
Florence 44
Secaucus 42
Genoa 41
Woodbridge 41
Denver 39
Tokyo 39
San Francisco 37
Brooklyn 36
Fairfield 36
Mexico City 35
Miano 35
Bari 34
Brussels 33
Poplar 31
Washington 31
Catania 30
London 30
Nuremberg 30
Stockholm 29
Fremont 27
Ottawa 26
Amsterdam 24
Da Nang 22
Belo Horizonte 20
Brno 20
Guangzhou 20
Verona 19
Ankara 18
Assago 18
Brescia 18
Palermo 18
Bucharest 16
Düsseldorf 16
Kunming 16
Mumbai 16
Nanjing 16
Rio de Janeiro 16
Trieste 16
Brasília 15
Totale 17.522
Salva come PNG Salva come JPEG
Nome #
EQ-5D-5L population norms for Italy 712
Esiti di salute e performance del Servizio Sanitario Nazionale 494
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 469
La funzione di HTA nelle aziende sanitarie italiane: un potenziale ancora inutilizzato? 447
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 405
I dispositivi medici in Italia: un settore, tanti mercati 355
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 336
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 332
Gli esiti di salute del Servizio Sanitario Nazionale 330
Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis 330
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration 320
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 300
La dimensione del settore dei dispositivi medici 290
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 290
Programma nazionale HTA per dispositivi medici: quali sfide per l’implementazione? 285
An economic perspective on urinary tract infection: the "costs of resignation" 283
An electronic patient-reported outcome mobile app for data collection in type a hemophilia: design and usability study 273
Gli esiti di salute del Servizio Sanitario Nazionale 266
Myth #5: health care is rightly left to the private sector, for the sake of efficiency 262
Current and Future Trends in the HTA of Medical Devices 261
Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis 261
A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study 259
Surrogate endpoints: a key concept in clinical epidemiology 258
A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement 255
Endpoint surrogati e politiche sanitarie: l’importanza di metodi di validazione adeguati 253
Integrating HTA principles into procurement of medical devices: the Italian national HTA programme for medical devices 250
A repeated cross-sectional analysis on the economic impact of SARS-CoV-2 pandemic at the hospital level in Italy 246
Early budget impact analysis of magnetic balloon technology for facilitating the completion of difficult colonoscopies 242
A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis 240
Broadening the concept of value: a scoping review on the option value of medical technologies 240
I processi di valutazione dei dispositivi medici e delle tecnologie sanitarie 239
Hospital-based HTA: quale valore per la valutazione delle tecnologie nelle Aziende Sanitarie italiane? 238
Distinguishing features in the assessment of mHealth apps 233
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses 230
Mapping payment and pricing schemes for health innovation: protocol of a scoping literature review 228
Surrogate endpoints in trials-a call for better reporting 226
The Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer 220
Coverage with evidence development for medical devices in Europe: can practice meet theory? 220
A more evidence based approach to the use of surrogate end points in policy making 219
Value-based healthcare: il nuovo approccio di AIFA alla determinazione multidimensionale del valore 219
Measuring value in health care: a comparative analysis of value-based frameworks 215
Esiti di salute e performance del Servizio Sanitario Nazionale 214
Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal 214
La gestione dell'innovazione tecnologica in sanità: analisi e confronto di alcune politiche regionali in Italia 213
European diabetes research and its funding, 2002–2013 213
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges 213
Esiti di salute e performance del Servizio Sanitario Nazionale 212
Strumenti a supporto del processo decisionale condiviso in oncologia 211
Cost–effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma 211
Assessment of nonfatal myocardial infarction as a surrogate for all-cause and cardiovascular mortality in treatment or prevention of coronary artery disease: a meta-analysis of randomized clinical trials 210
Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: results from the PRO4All project 208
Valutare l’impatto dell’HTA come strumento di governo dell’innovazione tecnologica: modelli teorici e studi empirici 208
Harnessing digital health technologies during and after the COVID-19 pandemic: context matters 206
Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials 206
Surrogate endpoints in health technology assessment: an international review of methodological guidelines 204
Esiti di salute e performance del Servizio Sanitario Nazionale 202
Corona-regionalism? Differences in regional responses to COVID-19 in Italy 202
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer 200
Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis 198
Design and features of pricing and payment schemes for health technologies: a scoping review and a proposal for a flexible need-driven classification 194
Implementing shared decision-making interventions in breast cancer clinical practice: a scoping review 194
Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. 194
An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations 192
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? 192
The Coronavirus pandemic and inequality in Italy 189
The impact of surgical experience in VATS lobectomy on conversion and patient quality of life: results from a comprehensive national video-assisted thoracic surgical database 187
Comparing drug and non-drug technologies in comparative effectiveness research 187
Associations between surrogate markers and clinical outcomes for nononcologic chronic disease treatments 185
Esiti di salute e performance del Servizio Sanitario Nazionale 185
Non-communicable diseases: mapping research funding organisations, funding mechanisms and research practices in Italy and Germany 185
Core outcome set in surgical oncology: why, what and how to measure 185
Valorizzare gli esiti riferiti dal paziente : opportunità e sfide 182
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients 182
Mud-bath therapy in addition to usual care in bilateral knee osteoarthritis: economic evaluation alongside a randomized controlled trial 181
A call for better reporting of trials using surrogate primary endpoints 178
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials 178
Introduction to economic evaluation and health technology assessment 176
Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? 176
Time to review the role of surrogate end points in health policy: state of the art and the way forward 172
Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments 171
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 170
A Strategic Roadmap to Support Communication on and Acceptance of Surrogate Endpoints: The REnal Surrogacy accEpTance in Chronic Kidney Disease (RESET CKD) Collaboration 169
Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers 169
The development of an Archive of Patient-Reported Outcome Measures (PROMs) in Oncology: The Italian PRO4All Project 167
Surrogate endpoints in randomised trials of physiotherapy interventions: the SPIRIT and CONSORT extension checklists for better reporting 166
Validation of exercise capacity as a surrogate endpoint in exercise-based rehabilitation for heart failure: a meta-analysis of randomized controlled trials 166
Exercise training for chronic heart failure (ExTraMATCH II): why all data are not equal 166
Machine learning-assisted health economics and policy reviews: a comparative assessment 165
The impacts of diabetes research from 31 European Countries in 2002 to 2013 165
Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps 165
Determinants of demand for total hip and and knee arthroplasty: a systematic literature review 163
Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy 161
The evaluation of medical devices: are we getting closer to solve the puzzle? A review of recent trends 161
The role of patient-reported outcomes in reimbursement decisions and drug innovation in Italy 161
Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence 159
Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study 158
Transparent and complete reporting of surrogate endpoints in trials: the SPIRIT-Surrogate and CONSORT-Surrogate extensions 156
Health technology assessment methods guidelines for medical devices: how can we address the gaps? the international federation of medical and biological engineering perspective 156
Value attribution for combination treatments: two potential solutions for an insoluble problem 155
Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study 154
Totale 22.893
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.366
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.123 0 0 0 68 140 66 58 233 72 145 143 198
2022/20233.178 202 173 86 266 203 223 83 162 1.398 121 161 100
2023/20242.436 109 142 149 59 258 287 193 324 98 180 303 334
2024/20253.372 108 71 228 172 179 195 276 245 961 384 341 212
2025/202613.021 758 986 365 850 1.023 463 1.387 1.224 3.492 1.542 586 345
2026/20273.226 540 708 916 1.062 0 0 0 0 0 0 0 0
Totale 30.612